Compounds > lenalidomide
Page last updated: 2024-09-05

lenalidomide and cabozantinib

lenalidomide has been researched along with cabozantinib in 2 studies

Compound Research Comparison

Studies
(lenalidomide)		Trials
(lenalidomide)		Recent Studies (post-2010)
(lenalidomide)		Studies
(cabozantinib)		Trials
(cabozantinib)		Recent Studies (post-2010) (cabozantinib)
3,5327252,850731127716

Protein Interaction Comparison

ProteinTaxonomylenalidomide (IC50)cabozantinib (IC50)
Epidermal growth factor receptorHomo sapiens (human)1.118
High affinity nerve growth factor receptorHomo sapiens (human)0.0723
Acyl-CoA desaturase 1Rattus norvegicus (Norway rat)0.0013
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)0.1699
Hepatocyte growth factor receptorHomo sapiens (human)0.0791
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.0108
Fibroblast growth factor receptor 1Homo sapiens (human)0.0113
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.178
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.012
Tyrosine-protein kinase receptor UFOHomo sapiens (human)0.5617
Kinesin-1 heavy chainHomo sapiens (human)0.19
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.006
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.3151
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.8877
Angiopoietin-1 receptorHomo sapiens (human)0.0143
Macrophage-stimulating protein receptorHomo sapiens (human)0.069
Coiled-coil domain-containing protein 6Homo sapiens (human)0.4615
SAFB-like transcription modulatorHomo sapiens (human)0.0013

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES1

Reviews

1 review(s) available for lenalidomide and cabozantinib

ArticleYear
Novel molecular targeted therapies for refractory thyroid cancer.
    Head & neck, 2012, Volume: 34, Issue:5

    Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat

2012

Other Studies

1 other study(ies) available for lenalidomide and cabozantinib

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013